The Food and Drug Administration continues to recommend that health care professionals inspect all current and future intravenous saline solution bags to ensure they are not simulated products made by Wallcur LLC for training purposes. On Dec. 30, FDA alerted health care professionals not to use Wallcur simulated IV products in human or animal patients after learning that some of the products had been distributed to medical clinics, surgical centers and urgent care facilities and administered to patients. Wallcur recalled the products last month and is working with FDA to revise its labeling and marketing practices to prevent a recurrence, the agency said. According to FDA, more than 40 patients received infusions of the simulated products, some of whom experienced adverse events such as fever, chills, tremors and headache. Health care professionals should report any suspected adverse events following use of the products to FDA’s MedWatch program.

Related News Articles

Headline
The National Collaborative for Improving the Clinical Learning Environment this week released guidance to help health care system leaders work with clinical…
Headline
The Centers for Medicare & Medicaid Services should continue to work with national standards body X12 to include the new unique device identifier on its…
Headline
The Centers for Disease Control and Prevention today issued recommendations to help health care providers and laboratories prevent the spread of Candida auris…
Headline
Inpatient rehabilitation facilities and long-term care hospitals have until Sept. 30 to review their 2016 quality data before it is publicly reported on the…
Headline
The Institute for Safe Medication Practices yesterday released a tool to help hospitals and outpatient facilities evaluate their safety practices for “…
Headline
The Centers for Medicare & Medicaid Services seeks comments through Nov. 20 on a “new direction” for its Innovation Center that will approach…